{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:45:40Z","timestamp":1791906340851,"version":"4.3.4"},"reference-count":179,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Obesity is a multifactorial chronic disease characterized by an excess of adipose tissue, affecting people of all ages. In the last 40 years, the incidence of overweight and obesity almost tripled worldwide. The accumulation of \u201cvisceral\u201d adipose tissue increases with aging, leading to several cardio-metabolic consequences: from increased blood pressure to overt arterial hypertension, from insulin-resistance to overt type 2 diabetes mellitus (T2DM), dyslipidemia, chronic kidney disease (CKD), and obstructive sleep apnea. The increasing use of innovative drugs, namely glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2-i), is changing the management of obesity and its related cardiovascular complications significantly. These drugs, first considered only for T2DM treatment, are now used in overweight patients with visceral adiposity or obese patients, as obesity is no longer just a risk factor but a critical condition at the basis of common metabolic, cardiovascular, and renal diseases. An adipocentric vision and approach should become the cornerstone of visceral overweight and obesity integrated management and treatment, reducing and avoiding the onset of obesity-related multiple risk factors and their clinical complications. According to recent progress in basic and clinical research on adiposity, this narrative review aims to contribute to a novel clinical approach focusing on pathophysiological and therapeutic insights.<\/jats:p>","DOI":"10.3389\/fmed.2024.1365183","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T04:57:45Z","timestamp":1712552265000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities"],"prefix":"10.3389","volume":"11","author":[{"given":"Riccardo","family":"Sarzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Landolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Di Pentima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Ortensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Falcioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Massacesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Rampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Spannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Giulietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1093\/eurjpc\/zwac187","article-title":"Obesity and cardiovascular disease: mechanistic insights and management strategies: a joint position paper by the World Heart Federation and World Obesity Federation","volume":"29","author":"Lopez-Jimenez","year":"2022","journal-title":"Eur J Prev Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1136340","DOI":"10.3389\/fcvm.2023.1136340","article-title":"Obesity and cardiovascular disease: an executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC)","volume":"10","author":"Volpe","year":"2023","journal-title":"Front Cardiovasc Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","article-title":"Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies","volume":"373","author":"Whitlock","year":"2009","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.18553\/jmcp.2021.20410","article-title":"Direct medical costs of obesity in the United States and the most populous states","volume":"27","author":"Cawley","year":"2021","journal-title":"J Manag care Spec Pharm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.pcl.2011.09.006","article-title":"Etiologies of obesity in children: nature and nurture","volume":"58","author":"Skelton","year":"2011","journal-title":"Pediatr Clin North Am."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.ijo.0803005","article-title":"Health consequences of obesity in the elderly: a review of four unresolved questions","volume":"29","author":"Zamboni","year":"2005","journal-title":"Int J Obes."},{"key":"B9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41576-021-00414-z","article-title":"The genetics of obesity: from discovery to biology","volume":"23","author":"Loos","year":"2022","journal-title":"Nat Rev Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1161\/CIRCULATIONAHA.117.029617","article-title":"Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management","volume":"137","author":"Neeland","year":"2018","journal-title":"Circulation."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity phenotypes, diabetes, and cardiovascular diseases","volume":"126","author":"Pich\u00e9","year":"2020","journal-title":"Circ Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000988","article-title":"Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association","volume":"144","author":"Yeghiazarians","year":"2021","journal-title":"Circulation."},{"key":"B13","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1056\/NEJMra2032804","article-title":"Reassessing human adipose tissue","volume":"386","author":"Cypess","year":"2022","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00125-021-05484-6","article-title":"Are people with metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK Biobank participants","volume":"64","author":"Zhou","year":"2021","journal-title":"Diabetologia."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1111\/obr.12742","article-title":"Revisiting the evolutionary origins of obesity: lazy vs. peppy-thrifty genotype hypothesis","volume":"19","author":"Reddon","year":"2018","journal-title":"Obes Rev an Off J Int Assoc Study Obes."},{"key":"B16","doi-asserted-by":"publisher","first-page":"R104","DOI":"10.1152\/ajpregu.00499.2015","article-title":"Insulin\/glucose induces natriuretic peptide clearance receptor in human adipocytes: a metabolic link with the cardiac natriuretic pathway","volume":"311","author":"Bordicchia","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1172\/JCI59701","article-title":"Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes","volume":"122","author":"Bordicchia","year":"2012","journal-title":"J Clin Invest."},{"key":"B18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41569-018-0097-6","article-title":"The role of adipose tissue in cardiovascular health and disease","volume":"16","author":"Oikonomou","year":"2019","journal-title":"Nat Rev Cardiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3109\/07853890.2010.526138","article-title":"Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study)","volume":"44","author":"Hiuge-Shimizu","year":"2012","journal-title":"Ann Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1172\/JCI45887","article-title":"Adipose tissue remodeling and obesity","volume":"121","author":"Sun","year":"2011","journal-title":"J Clin Invest."},{"key":"B21","doi-asserted-by":"publisher","first-page":"154893","DOI":"10.1016\/j.metabol.2021.154893","article-title":"The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: a population-based cohort study","volume":"128","author":"Kouvari","year":"2022","journal-title":"Metabolism."},{"key":"B22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jcmg.2023.01.022","article-title":"Myocardial tissue-level characteristics of adults with metabolically healthy obesity","volume":"16","author":"Zhao","year":"2023","journal-title":"JACC Cardiovasc Imaging."},{"key":"B23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1467-789X.2011.00952.x","article-title":"Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis","volume":"13","author":"Ashwell","year":"2012","journal-title":"Obes Rev an Off J Int Assoc Study Obes."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/eurheartj\/ehad083","article-title":"Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox","volume":"44","author":"Butt","year":"2023","journal-title":"Eur Heart J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1172\/JCI22422","article-title":"Molecular mediators of hepatic steatosis and liver injury","volume":"114","author":"Browning","year":"2004","journal-title":"J Clin Invest."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"EASL","year":"2016","journal-title":"J Hepatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1097\/HEP.0000000000000696","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"696","author":"Rinella","year":"2023","journal-title":"Ann Hepatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/oby.2000.79","article-title":"Body mass index and the prevalence of hypertension and dyslipidemia","volume":"8","author":"Brown","year":"2000","journal-title":"Obes Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/HJH.0000000000000010","article-title":"Excess dietary sodium and inadequate potassium intake by hypertensive patients in Italy: results of the MINISAL-SIIA study program","volume":"32","author":"Galletti","year":"2014","journal-title":"J Hypertens."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1097\/00004872-200412000-00019","article-title":"Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives","volume":"22","author":"Grassi","year":"2004","journal-title":"J Hypertens."},{"key":"B31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1749-6632.1999.tb07788.x","article-title":"Mechanisms of hypertension and kidney disease in obesity","volume":"892","author":"Hall","year":"1999","journal-title":"Ann N Y Acad Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/HJH.0b013e3282f624a0","article-title":"Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans","volume":"26","author":"Sarzani","year":"2008","journal-title":"J Hypertens."},{"key":"B33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1530\/JME-22-0196","article-title":"Phospholipase D mediates very low-density lipoprotein-induced aldosterone production, in part, via lipin-1","volume":"70","author":"Spaulding","year":"2023","journal-title":"J Mol Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/ajh.2012.47","article-title":"Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment","volume":"25","author":"Sarzani","year":"2012","journal-title":"Am J Hypertens."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1097\/HJH.0000000000001438","article-title":"Plasma renin activity to plasma aldosterone concentration ratio correlates with night-time and pulse pressures in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors\/AT1 blockers","volume":"35","author":"Spannella","year":"2017","journal-title":"J Hypertens."},{"key":"B36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40292-017-0196-1","article-title":"Cardiac natriuretic peptides, hypertension and cardiovascular risk","volume":"24","author":"Sarzani","year":"2017","journal-title":"High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2214415","DOI":"10.3390\/ijms232214415","article-title":"Role of cardiac natriuretic peptides in heart structure and function","volume":"23","author":"Sarzani","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.0000112582.16683.EA","article-title":"Impact of obesity on plasma natriuretic peptide levels","volume":"109","author":"Wang","year":"2004","journal-title":"Circulation."},{"key":"B39","doi-asserted-by":"publisher","first-page":"81961","DOI":"10.3390\/biomedicines10081961","article-title":"Plasma levels of proprotein convertase subtilisin\/kexin type 9 are inversely associated with N-terminal pro B-type natriuretic peptide in older men and women","volume":"10","author":"Spannella","year":"2022","journal-title":"Biomedicines"},{"key":"B40","doi-asserted-by":"publisher","first-page":"dgad330","DOI":"10.1210\/clinem\/dgad330","article-title":"Obesity, hyperfiltration and early kidney damage: a new formula for the estimation of creatinine clearance","volume":"2023","author":"Basolo","year":"2023","journal-title":"J Clin Endocrinol Metab."},{"key":"B41","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0939-4753(03)80018-2","article-title":"Role of the natriuretic peptide system in lipogenesis\/lipolysis","volume":"13","author":"Dess\u00ec-Fulgheri","year":"2003","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1097\/00004872-199511000-00004","article-title":"Fasting inhibits natriuretic peptides clearance receptor expression in rat adipose tissue","volume":"13","author":"Sarzani","year":"1995","journal-title":"J Hypertens."},{"key":"B43","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1161\/01.HYP.33.2.658","article-title":"Low calorie diet enhances renal, hemodynamic, and humoral effects of exogenous atrial natriuretic peptide in obese hypertensives","volume":"33","author":"Dess\u00ec-Fulgheri","year":"1999","journal-title":"Hypertens"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e029062","DOI":"10.1161\/JAHA.122.029062","article-title":"Body composition and risk of incident heart failure in 1 million adults: a systematic review and dose-response meta-analysis of prospective cohort studies","volume":"12","author":"Oguntade","year":"2023","journal-title":"J Am Heart Assoc."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1002\/ejhf.3036","article-title":"Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the Heart Failure Association of the ESC","volume":"2023","author":"Bayes-Genis","year":"2023","journal-title":"Eur J Heart Fail."},{"key":"B46","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1001\/archinte.164.8.892","article-title":"Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation","volume":"164","author":"Hu","year":"2004","journal-title":"Arch Intern Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"111315","DOI":"10.1016\/j.biopha.2021.111315","article-title":"Adipose tissue and insulin resistance in obese","volume":"137","author":"Ahmed","year":"2021","journal-title":"Biomed Pharmacother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","author":"Gregg","year":"2016","journal-title":"lancet Diabetes Endocrinol."},{"key":"B50","first-page":"504","article-title":"Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity","volume":"11","author":"Henning","year":"2021","journal-title":"Am J Cardiovasc Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"84108","DOI":"10.3390\/ijms22084108","article-title":"The mechanisms of the development of atherosclerosis in prediabetes","volume":"22","author":"Liang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e212612","DOI":"10.1001\/jamanetworkopen.2021.2612","article-title":"The triglyceride-glucose index and obesity-related risk of end-stage kidney disease in Austrian adults","volume":"4","author":"Fritz","year":"2021","journal-title":"J Am Med Assoc Netw Open."},{"key":"B53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2337\/diacare.23.1.57","article-title":"Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity","volume":"23","author":"Bonora","year":"2000","journal-title":"Diabetes Care."},{"key":"B54","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jacc.2019.11.044","article-title":"Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers: JACC state-of-the-art review","volume":"75","author":"Mechanick","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jacc.2021.05.035","article-title":"Management of obesity in cardiovascular practice: JACC focus seminar","volume":"78","author":"Despr\u00e9s","year":"2021","journal-title":"J Am Coll Cardiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12325-019-00941-6","article-title":"Prevalence and control of dyslipidemia in patients referred for high blood pressure: the disregarded \u201cdouble-trouble\u201d lipid profile in overweight\/obese","volume":"19","author":"Spannella","year":"2019","journal-title":"Adv Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"111","DOI":"10.15829\/1560-4071-2020-3826","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41574-021-00512-2","article-title":"Type 2 diabetes mellitus in older adults: clinical considerations and management","volume":"17","author":"Bellary","year":"2021","journal-title":"Nat Rev Endocrinol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40292-020-00396-9","article-title":"Pharmacological approach to smoking cessation: an updated review for daily clinical practice","volume":"20","author":"Giulietti","year":"2020","journal-title":"High Blood Press Cardiovasc Prev."},{"key":"B60","first-page":"1345","article-title":"Obesity hypoventilation syndrome: a state-of-the-art review","volume":"55","author":"Mokhlesi","year":"2010","journal-title":"Respir Care."},{"key":"B61","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1161\/01.HYP.0000174243.39897.6c","article-title":"Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity","volume":"46","author":"Grassi","year":"2005","journal-title":"Hypertens."},{"key":"B62","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40292-021-00484-4","article-title":"Sleep apnea and hypertension","volume":"29","author":"Seravalle","year":"2022","journal-title":"High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens."},{"key":"B63","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1210\/endrev\/bnaa025","article-title":"Microvascular dysfunction in diabetes mellitus and cardiometabolic disease","volume":"42","author":"Horton","year":"2021","journal-title":"Endocr Rev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e52708","DOI":"10.1371\/journal.pone.0052708","article-title":"Obesity and the microvasculature: a systematic review and meta-analysis","volume":"8","author":"Boillot","year":"2013","journal-title":"PLoS ONE."},{"key":"B65","doi-asserted-by":"publisher","first-page":"95202","DOI":"10.3390\/ijms23095202","article-title":"Obesity as a risk factor for dementia and Alzheimer's disease: the role of leptin","volume":"23","author":"Flores-Cordero","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11011-022-01100-7","article-title":"Hyperglycemia with or without insulin resistance triggers different structural changes in brain microcirculation and perivascular matrix","volume":"38","author":"\u00d6zkan","year":"2023","journal-title":"Metab Brain Dis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jcmg.2023.01.016","article-title":"Ischemic heart disease and vascular risk factors are associated with accelerated brain aging","volume":"16","author":"Rauseo","year":"2023","journal-title":"JACC Cardiovasc Imaging."},{"key":"B68","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J."},{"key":"B69","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J."},{"key":"B70","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1210\/er.2017-00253","article-title":"The science of obesity management: an endocrine society scientific statement","volume":"39","author":"Bray","year":"2018","journal-title":"Endocr Rev."},{"key":"B71","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2458-14-14","article-title":"Beyond BMI: the \u201cMetabolically healthy obese\u201d phenotype and its association with clinical\/subclinical cardiovascular disease and all-cause mortality\u2014a systematic review","volume":"14","author":"Roberson","year":"2014","journal-title":"BMC Public Health."},{"key":"B72","doi-asserted-by":"publisher","first-page":"9324","DOI":"10.1038\/s41598-020-66095-6","article-title":"Association of body surface scanner-based abdominal volume with parameters of the Metabolic Syndrome and comparison with manually measured waist circumference","volume":"10","author":"Jaeschke","year":"2020","journal-title":"Sci Rep."},{"key":"B73","doi-asserted-by":"publisher","first-page":"22185","DOI":"10.1038\/s41598-022-26740-8","article-title":"Body surface scan anthropometrics are related to cardiorespiratory fitness in the general population","volume":"12","author":"K\u00f6hler","year":"2022","journal-title":"Sci Rep."},{"key":"B74","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/bmj.312.7027.377","article-title":"Ratio of waist circumference to height may be better indicator of need for weight management","volume":"312","author":"Ashwell","year":"1996","journal-title":"Br Med J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/ije\/dyi253","article-title":"What aspects of body fat are particularly hazardous and how do we measure them?","volume":"35","author":"Snijder","year":"2006","journal-title":"Int J Epidemiol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3238\/arztebl.2020.0659a","article-title":"Waist-hip ratio more appropriate than body mass index","volume":"117","author":"Haufs","year":"2020","journal-title":"Dtsch Arztebl Int."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e103483","DOI":"10.1371\/journal.pone.0103483","article-title":"Waist-to-height ratio is more predictive of years of life lost than body mass index","volume":"9","author":"Ashwell","year":"2014","journal-title":"PLoS ONE."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1132006","DOI":"10.3389\/fnut.2023.1132006","article-title":"Central adiposity as a predictor of mortality in older adults: identification of cutoffs using generalized additive models","volume":"10","author":"Fernandes","year":"2023","journal-title":"Front Nutr."},{"key":"B79","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40519-019-00677-w","article-title":"The \u201chyper-triglyceridemic waist phenotype\u201d is a reliable marker for prediction of accumulation of abdominal visceral fat in Chinese adults","volume":"25","author":"Tian","year":"2020","journal-title":"Eat Weight Disord."},{"key":"B80","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3305\/nh.2014.30.1.7411","article-title":"Hypertriglyceridemic waist phenotype: association with metabolic disorders and visceral fat in adults","volume":"30","author":"Cunha de Oliveira","year":"2014","journal-title":"Nutr Hosp."},{"key":"B81","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12933-023-01762-2","article-title":"Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data","volume":"22","author":"Che","year":"2023","journal-title":"Cardiovasc Diabetol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/jch.14305","article-title":"The association of triglyceride and glucose index, and triglyceride to high-density lipoprotein cholesterol ratio with prehypertension and hypertension in normoglycemic subjects: a large cross-sectional population study","volume":"23","author":"Zhang","year":"2021","journal-title":"J Clin Hypertens."},{"key":"B83","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12902-022-01180-7","article-title":"Relationship between a novel non-insulin-based metabolic score for insulin resistance (METS-IR) and coronary artery calcification","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Endocr Disord."},{"key":"B84","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40618-022-01925-0","article-title":"The impact of the metabolic score for insulin resistance on cardiovascular disease: a 10-year follow-up cohort study","volume":"46","author":"Wu","year":"2023","journal-title":"J Endocrinol Invest."},{"key":"B85","doi-asserted-by":"publisher","first-page":"730827","DOI":"10.1155\/2014\/730827","article-title":"Visceral adiposity index: an indicator of adipose tissue dysfunction","volume":"2014","author":"Amato","year":"2014","journal-title":"Int J Endocrinol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12944-023-01802-6","article-title":"Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis","volume":"22","author":"Ebrahimi","year":"2023","journal-title":"Lipids Health Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.clnu.2019.07.012","article-title":"Metabolic Score for Visceral Fat (METS-VF), a novel estimator of intra-abdominal fat content and cardio-metabolic health","volume":"39","author":"Bello-Chavolla","year":"2020","journal-title":"Clin Nutr."},{"key":"B88","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","article-title":"Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials","volume":"42","author":"Neter","year":"2003","journal-title":"Hypertens"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension the Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens."},{"key":"B91","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1093\/ndt\/gfn379","article-title":"Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption","volume":"23","author":"Chagnac","year":"2008","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc."},{"key":"B92","doi-asserted-by":"publisher","first-page":"665023","DOI":"10.3389\/fmed.2021.665023","article-title":"Looking for crumbs in the obesity forest: anti-obesity interventions and obesity-associated cardiometabolic traits in the Mexican population. History and systematic review with meta-analyses","volume":"8","author":"Garcia-Oropesa","year":"2021","journal-title":"Front Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.clnu.2022.01.024","article-title":"ESPEN practical guideline: clinical nutrition and hydration in geriatrics","volume":"41","author":"Volkert","year":"2022","journal-title":"Clin Nutr."},{"key":"B94","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.soard.2022.11.004","article-title":"Weight loss specific to indication, remission of diabetes, and short-term complications after sleeve gastrectomy conversion to Roux-en-Y gastric bypass: a systematic review and meta-analysis","volume":"19","author":"Fehervari","year":"2023","journal-title":"Surg Obes Relat Dis Off J Am Soc Bariatr Surg."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e2616","DOI":"10.1097\/MD.0000000000002616","article-title":"Differential effects of bariatric surgery vs. exercise on excessive visceral fat deposits","volume":"95","author":"Wu","year":"2016","journal-title":"Medicine."},{"key":"B96","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1517\/14740338.2014.909405","article-title":"Drug safety evaluation of naltrexone\/bupropion for the treatment of obesity","volume":"13","author":"Verpeut","year":"2014","journal-title":"Expert Opin Drug Saf."},{"key":"B97","doi-asserted-by":"publisher","first-page":"111789","DOI":"10.1016\/j.biopha.2021.111789","article-title":"Diets and drugs for weight loss and health in obesity\u2014an update","volume":"140","author":"Aaseth","year":"2021","journal-title":"Biomed Pharmacother."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2014.04.004","article-title":"Naltrexone\/bupropion for obesity: an investigational combination pharmacotherapy for weight loss","volume":"84","author":"Billes","year":"2014","journal-title":"Pharmacol Res."},{"key":"B99","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide vs. placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes."},{"key":"B102","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 30 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.2337\/dc19-0415","article-title":"Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial","volume":"42","author":"Nauck","year":"2019","journal-title":"Diabetes Care."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1001\/jamainternmed.2022.3810","article-title":"Acute cholecystitis associated with the use of glucagon-like peptide-1 receptor agonists reported to the US Food and Drug Administration","volume":"182","author":"Woronow","year":"2022","journal-title":"J Am Med Assoc Intern Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000516418","article-title":"Excess body weight and gallstone disease","volume":"37","author":"Stokes","year":"2021","journal-title":"Visc Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1111\/dom.13420","article-title":"Effects of liraglutide on gallbladder emptying: a randomized, placebo-controlled trial in adults with overweight or obesity","volume":"20","author":"Nex\u00f8e-Larsen","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"B107","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/dom.14890","article-title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses","volume":"25","author":"Kosiborod","year":"2023","journal-title":"Diabetes Obes Metab."},{"key":"B108","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs. placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"J Am Med Assoc."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the step 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"J Am Med Assoc."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.jacc.2023.09.811","article-title":"Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction","volume":"82","author":"Butler","year":"2023","journal-title":"J Am Coll Cardiol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"102849","DOI":"10.1016\/j.dsx.2023.102849","article-title":"Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"17","author":"Bandyopadhyay","year":"2023","journal-title":"Diabetes Metab Syndr."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1111\/dom.15058","article-title":"Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial","volume":"25","author":"McGuire","year":"2023","journal-title":"Diabetes Obes Metab."},{"key":"B118","doi-asserted-by":"publisher","first-page":"186052","DOI":"10.3390\/jcm12186052","article-title":"Real-world retrospective study into the effects of oral semaglutide (as a switchover or add-on therapy) in type 2 diabetes","volume":"12","author":"Candido","year":"2023","journal-title":"J Clin Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s12020-023-03636-9","article-title":"The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis","volume":"83","author":"Wu","year":"2023","journal-title":"Endocrine."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1240263","DOI":"10.3389\/fendo.2023.1240263","article-title":"Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study","volume":"14","author":"Volpe","year":"2023","journal-title":"Front Endocrinol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","article-title":"Efficacy and safety of glucagon-like-peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis","volume":"30","author":"Haq Ansari","year":"2023","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","article-title":"The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets","volume":"5","author":"El","year":"2023","journal-title":"Nat Metab."},{"key":"B123","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes Metab."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am Heart J."},{"key":"B126","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2023","journal-title":"J Am Med Assoc."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.2337\/dc23-1135","article-title":"Predictors of \u226515% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide in adults with type 2 diabetes in SURPASS 1-4","volume":"46","author":"Ma\u0142ecki","year":"2023","journal-title":"Diabetes Care."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs. insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"J Am Med Assoc."},{"key":"B130","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet."},{"key":"B131","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med."},{"key":"B132","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bl\u00fcher","year":"2023","journal-title":"Diabetologia."},{"key":"B133","doi-asserted-by":"publisher","first-page":"6666","DOI":"10.1038\/s41598-022-10577-2","article-title":"Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis","volume":"12","author":"Nestor","year":"2022","journal-title":"Sci Rep."},{"key":"B134","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMe2307282","article-title":"Triple G agonists\u2014a home run for obesity?","volume":"389","author":"Patti","year":"2023","journal-title":"N Engl J Med."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jama.2024.2252","article-title":"GLP-1 agonists for obesity\u2014a new recipe for success?","volume":"331","author":"Mozaffarian","year":"2024","journal-title":"J Am Med Assoc"},{"key":"B137","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J."},{"key":"B138","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2337\/dc23-S002","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabet Care"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm-\u22122020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"B141","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ijcard.2022.03.032","article-title":"The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis","volume":"357","author":"Avogaro","year":"2022","journal-title":"Int J Cardiol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy vs. placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Neeland","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"B145","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide vs. once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide vs. exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care."},{"key":"B147","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide vs. once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, mu","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"B150","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2337\/dc22-1889","article-title":"Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials","volume":"46","author":"Heerspink","year":"2023","journal-title":"Diabetes Care."},{"key":"B151","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"key":"B152","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.numecd.2020.05.030","article-title":"Sodium-glucose co-transporter-2 inhibitors: peculiar \u201chybrid\u201d diuretics that protect from target organ damage and cardiovascular events","volume":"30","author":"Sarzani","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"B154","doi-asserted-by":"publisher","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for tubular Na(+)\/H(+) exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin","volume":"319","author":"Onishi","year":"2020","journal-title":"Am J Physiol Renal Physiol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/jamacardio.2022.3736","article-title":"Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction: a participant-level pooled analysis of DAPA-HF and DELIVER","volume":"7","author":"Desai","year":"2022","journal-title":"J Am Med Assoc Cardiol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.cardfail.2021.05.012","article-title":"Empagliflozin in heart failure with predicted preserved vs. reduced ejection fraction: data from the EMPA-REG OUTCOME trial","volume":"27","author":"Savarese","year":"2021","journal-title":"J Card Fail."},{"key":"B162","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study","volume":"9","author":"Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"JACC Heart Fail."},{"key":"B163","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"B164","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","article-title":"Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial","volume":"143","author":"Ye","year":"2021","journal-title":"Circulation."},{"key":"B166","doi-asserted-by":"publisher","first-page":"20406223221102750","DOI":"10.1177\/20406223221102754","article-title":"Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient","volume":"13","author":"Sarzani","year":"2022","journal-title":"Ther Adv Chronic Dis."},{"key":"B167","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/HJH.0b013e3282f47675","article-title":"Angiotensin receptor blockers: dose does matter","volume":"26","author":"Sarzani","year":"2008","journal-title":"J Hypertens"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1097\/HJH.0b013e328277596e","article-title":"Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus","volume":"25","author":"Hollenberg","year":"2007","journal-title":"J Hypertens."},{"key":"B169","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med."},{"key":"B170","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1681\/ASN.2010090969","article-title":"ACE inhibition is renoprotective among obese patients with proteinuria","volume":"22","author":"Mallamaci","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2165\/11632080-000000000-00000","article-title":"Obesity and hypertension in cardiac hypertrophy: two sides of the same coin?","volume":"19","author":"Sarzani","year":"2012","journal-title":"High Blood Press Cardiovasc Prev."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3317\/jraas.2008.007","article-title":"Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension","volume":"9","author":"Gojanovic","year":"2008","journal-title":"J Renin Angiotensin Aldosterone Syst."},{"key":"B174","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"J Am Med Assoc."},{"key":"B176","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep."},{"key":"B177","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","article-title":"Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index \u226527 kg\/m2: SURMOUNT-1 ambulatory blood pressure monitoring substudy","volume":"81","author":"de Lemos","year":"2024","journal-title":"Hypertens"},{"key":"B178","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12933-020-01164-8","article-title":"Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics","volume":"19","author":"Morieri","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2019.02.028","article-title":"Statins and nonalcoholic fatty liver disease in the era of precision medicine: more friends than foes","volume":"284","author":"Nascimbeni","year":"2019","journal-title":"Atherosclerosis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1365183\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T04:57:49Z","timestamp":1712552269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1365183\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":179,"alternative-id":["10.3389\/fmed.2024.1365183"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1365183","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"article-number":"1365183"}}